APA (7th ed.) Citation

Garassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., . . . Paz-Ares, L. (2025). Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]. JTO clinical and research reports, 6(10), 100892. https://doi.org/10.1016/j.jtocrr.2025.100892

Chicago Style (17th ed.) Citation

Garassino, Marina C., et al. "Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]." JTO Clinical and Research Reports 6, no. 10 (2025): 100892. https://doi.org/10.1016/j.jtocrr.2025.100892.

MLA (9th ed.) Citation

Garassino, Marina C., et al. "Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]." JTO Clinical and Research Reports, vol. 6, no. 10, 2025, p. 100892, https://doi.org/10.1016/j.jtocrr.2025.100892.